Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections

Savara Inc. (NASDAQ:SVRA) is one of the top long-term biotechnology stocks to buy. On October 2, Savara Inc. (NASDAQ:SVRA) announced that its partner, TrilliumBiO, will present data on the development of a dried-serum assay at the upcoming CHEST 2025 conference.

TrilliumBiO is developing a dried-serum assay to enhance the detection of GM-CSF antibodies and aid in diagnosing autoimmune pulmonary alveolar proteinosis (aPAP). Additionally, Savara is to make a presentation on its investigational treatment, molgramostim, a recombinant human GM-CSF, currently in Phase 3 development for aPAP.

The presentation focuses on the company delivering positive results from the Phase 3 IMPALA-2 trial of molgramostim for treating autoimmune pulmonary alveolar proteinosis (aPAP). The results underlined the treatment’s ability to enhance lung diffusing capacity.

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Its lead product candidate is molgramostim (MOLBREEVI), an inhaled drug in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease.

While we acknowledge the potential of SVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVRA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.